Effect of levonorgestrel contraceptive implants, Norplant, on blood coagulation.
A longitudinal study of coagulation parameters was carried out on 47 women using the levonorgestrel subdermal implants, NORPLANT. The study comprised measurement of platelet count, prothrombin time, thrombin time, partial thromboplastin time with kaolin, clotting factors I, II, V and VI through XIII, plasminogen, antithrombin III (AT III), alpha 1 antitrypsin, alpha 2 macroglobulin and fibrinogen degradation products. The tests were done at admission and after one, three and six months of NORPLANT use. Parallel and similar studies were done on two groups of oral contraceptive users; the first group used a pill containing 1 mg norethisterone and 50 micrograms mestranol, and the second a pill consisting of 150 micrograms levonorgestrel and 30 micrograms ethinylestradiol. Results from this ongoing study have indicated that women using NORPLANT implants evidenced lack of effects on most of the parameters tested except for factor VII activity which was increased and AT III concentration which was decreased after six months of use. The combined pill users evidenced marked changes in the platelet count, the screening tests and in most of the coagulation-promoting factors; the changes were apparent after three months of use and became more pronounced after six months. The results demonstrate, with marked contrast, that the implants had less pronounced effects on the blood coagulation system than did the combined pills used in this study.
D000328:Adult; D000991:Antithrombins / Q000378:metabolism; D001777:Blood Coagulation / Q000187:drug effects*; D001779:Blood Coagulation Factors / Q000378:metabolism; D001780:Blood Coagulation Tests; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects; D004338:Drug Combinations; D004343:Drug Implants; D004997:Ethinyl Estradiol / Q000009:adverse effects; D019304:Ethinyl Estradiol-Norgestrel Combination; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D016912:Levonorgestrel; D008656:Mestranol / Q000009:adverse effects; D009640:Norethindrone / Q000009:adverse effects; D009644:Norgestrel / Q000009:adverse effects*
D000991:Antithrombins; D001779:Blood Coagulation Factors; D003277:Contraceptives, Oral, Combined; D004338:Drug Combinations; D004343:Drug Implants; D005338:Fibrin Fibrinogen Degradation Products; D009644:Norgestrel; D004997:Ethinyl Estradiol; D016912:Levonorgestrel; C014715:Norinyl; D019304:Ethinyl Estradiol-Norgestrel Combination; D008656:Mestranol; D009640:Norethindrone